ALXO (ALX Oncology Holdings) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALXO ALX Oncology Holdings Inc ALXO
31 GF Score
Price $2.00
! 3 Warning Signs
View Full Analysis

What is ALX Oncology Holdings FFO?

FFO (Funds from operations) only applies to REITs.

ALXO
31GF Score
ALX Oncology Holdings Inc ALXO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ALX Oncology Holdings Business Description

Address 323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score

Get the complete analysis for ALXO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price